LEGN Legend Biotech Corp IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1801198 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY64.0%
TTM net income YoY-67.7%
TTM EPS YoY-68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin61.4%
Operating margin—
Net margin-28.8%
FCF margin-12.5%
EBITDA margin—
Returns
ROE-29.1%
ROA-17.4%
ROIC (approx.)—
Asset turnover0.60x
Leverage & solvency
Liabilities / assets42.2%
Debt / equity0.32x
Current ratio1.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.03B | $627.30M |
| Cost of revenue | $397.10M | $216.40M |
| Gross profit | $631.80M | $410.90M |
| R&D expense | $414.70M | $413.50M |
| Operating income | -$136.50M | -$309.50M |
| Interest expense | $21.40M | $21.60M |
| Pretax income | -$282.60M | -$158.10M |
| Income tax | $14.20M | $18.90M |
| Net income | -$296.80M | -$177.03M |
| EPS (basic) | -0.81 | -0.48 |
| EPS (diluted) | -0.81 | -0.48 |
| Weighted avg. shares (diluted) | 368.64M | 365.70M |
| Balance sheet | ||
| Cash & equivalents | $901.90M | $286.70M |
| Receivables | $13.10M | $6.40M |
| Inventory | $32.00M | $23.90M |
| Current assets | $1.25B | $1.28B |
| PP&E, netmay include right-of-use assets (IFRS) | $116.30M | $99.30M |
| Intangibles | $1.90M | $2.20M |
| Total assets | $1.73B | $1.67B |
| Current liabilities | $636.40M | $277.70M |
| Short-term debt | $319.10M | $0 |
| Long-term debt | $0 | $301.20M |
| Total debt | $319.10M | $301.20M |
| Total liabilities | $731.60M | $629.60M |
| Shareholders' equity | $1.00B | $1.04B |
| Net debt | -$582.80M | $14.50M |
| Cash flow statement | ||
| Operating cash flow | -$100.20M | -$144.00M |
| Capital expenditure | $28.60M | $14.10M |
| Free cash flow | -$128.80M | -$158.10M |
| Investing cash flow | $709.60M | -$850.60M |
| Financing cash flow | -$300,000 | $5.70M |
| Stock-based compensation | $64.60M | $68.90M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.